A Single Center, Open-Labeled Exploratory Study to Evaluate a Novel Method for Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue of Type-1 Diabetic Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- glucose concentration at the subcutaneous insulin delivery site
研究概览
简要总结
The study seeks to use microdialysis and microperfusion techniques to assess the feasibility of performing insulin delivery and glucose sensing at a single subcutaneous tissue site.
详细描述
Glucose management in type 1 diabetic patients comprises the measurement of glucose in capillary blood obtained by fingersticking and administration of exogenous insulin in the form of a subcutaneous bolus injection or continuous subcutaneous infusion.
The present study seeks to test an alternative treatment approach that combines glucose measurement and insulin delivery at a single subcutaneous tissue site, thereby circumventing the need for fingerstick blood glucose monitoring. Microperfusion and microdialysis probes are applied in type 1 diabetic subjects to perform insulin delivery and glucose sampling at the same adipose tissue site. The feasibility of estimating blood glucose concentrations from the glucose levels measured at the subcutaneous insulin delivery site is then assessed during an overnight fast and an oral glucose tolerance test.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 1 diabetes mellitus patients aged 18 - 65
- •C-peptide negative (≤ 0.05 nmol/L)
- •HbA1c (glycosylated haemoglobin A1c) < 10%
- •Body Mass Index: 21 - 30 kg/m2
- •Informed consent obtained before any trial-related activities.
排除标准
- •Severe diabetic complications (e.g., proliferative retinopathy, severe nephropathy)
- •Female of childbearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods
- •Any condition that would interfere with trial participation or evaluation of results, as judged by the investigator
- •Treatment with drugs that could interfere with glucose metabolism and subcutaneous insulin absorption
- •Subject with mental incapacity or language barriers
结局指标
主要结局
glucose concentration at the subcutaneous insulin delivery site
时间窗: 20 hours
次要结局
未报告次要终点